∙ Als eerste resultaat van de exclusieve onderhandelingen die in juli zijn gestart, ondertekenen de twee bedrijven een wereldwijde distributieovereenkomst

∙ Na een eerste betaling van € 4 miljoen ontvangt BIOCORP een nieuwe betaling van € 2 miljoen bij ondertekening, gevolgd door extra mijlpaalbetalingen

∙ Met 300 miljoen verkochte insulinepennen per jaar is SANOFI een van de marktleiders

ISSOIRE, Frankrijk – (BUSINESS WIRE) – Regelgevend nieuws:

BIOCORP (Parijs: ALCOR) (FR0012788065 – ALCOR / Eligible PEA PME), een Frans bedrijf dat gespecialiseerd is in de ontwikkeling en productie van medische hulpmiddelen en slimme geneesmiddelenafgiftesystemen, kondigt vandaag de ondertekening aan van een wereldwijde samenwerkingsovereenkomst met SANOFI voor het gebruik van Mallya technologie, een verbonden apparaat voor insulinepennen.

Deze langetermijnovereenkomst is de eerste stap die voortvloeit uit exclusieve onderhandelingen die in juli 2019 zijn gestart. SANOFI en BIOCORP vervullen vandaag dus hun ambitie om een langdurige samenwerking aan te gaan op het gebied van diabetes.

BIOCORP and SANOFI Announce a Partnership to Fit SoloStar Insulin Pens With Mallya Technology Worldwide

∙ As a first result of the exclusive negotiations initiated in July, the two companies sign a global distribution agreement

∙ After an initial payment of €4 million, BIOCORP receives a new payment of €2 million upon signature, followed by additional milestone payments

∙ With 300 million insulin pens sold each year, SANOFI is one of the world leaders of the market

ISSOIRE, France–(BUSINESS WIRE)– Regulatory News:

BIOCORP (Paris:ALCOR) (FR0012788065 – ALCOR / Eligible PEA PME), a French company specializing in the development and manufacturing of medical devices and smart drug delivery systems, announces today the signature of a worldwide partnership agreement with SANOFI for the use of Mallya technology, a connected device for insulin pens.

This long-term agreement is the first decision resulting from exclusive negotiations initiated in July 2019. SANOFI and BIOCORP are thus fulfilling today their ambition to enter into a long-term partnership in the diabetes area.

The agreement covers two main points:

– Sanofi acquires the rights to a non-exclusive distribution of Mallya in its current version worldwide, starting in 2020.

– BIOCORP is committed to develop a specific and exclusive version of Mallya for SoloStar, SANOFI’s insulin pen.

As a result of the agreement, Sanofi is to pay BIOCORP a further €2 million upon signature of the contract (last July, BIOCORP received a first payment of €4 million). In addition, a third payment of €1.5 million is expected in 2020 when Mallya is effectively launched on the market.

BIOCORP will produce the Mallya devices at its production plant in Issoire, France.

Éric Dessertenne, Chief Operating Officer of BIOCORP, commented: “The expected and now confirmed signature of this contract provides a huge satisfaction to BIOCORP’s team. It confirms the promise of a long and successful partnership with SANOFI. As previously mentioned, Mallya has the potential to be a blockbuster thanks to the competitive advantages it brings to patients in monitoring the follow-up of their diabetes. Thanks to SANOFI’s global reach, this device will help improve compliance for the largest number of patients with diabetes. We are pleased to have our expertise recognized by a world leader in Life Sciences and are convinced that this is only the first step in Mallya’s history.”

ABOUT BIOCORP

Founded in 2004 in Issoire (near Clermont-Ferrand), France, BIOCORP is a French company specializing in the development and manufacturing of medical devices and innovative drug delivery systems. It is listed as ‘Innovative Company’ by the French public investment bank Bpifrance. With over twenty years of experience and more than 30 manufactured products, BIOCORP is a key player in the industry, providing drug delivery solutions that meet the evolving needs of patients. Today, BIOCORP continues to innovate in medical plastics, its core business, and to market traditional devices (alternative to aluminum capsules, syringe and vial administration systems) that have been an important source of recurring income. Its solid expertise and capacity to innovate have allowed the company to develop new Internet-connected products, including Mallya^TM, a smart cap for pen injectors that captures injection data and automatically transmits data to a mobile app, helping patients to manage their treatment. The company has a team of 45 employees. BIOCORP is listed on Euronext since July 2015 (FR0012788065 – ALCOR).

For more information, please visit www.biocorpsys.com
Follow us on Twitter @BIOCORPSystems

View source version on businesswire.com: https://www.businesswire.com/news/home/20191211005828/en/

Contacts

BIOCORP
Jacques Gardette

CEO

Éric Dessertenne

Chief Operating Officer

Sylvaine Dessard

Marketing & Communication Director

investisseurs@biocorp.fr
rp@biocorp.fr
+ 33 (0)6 88 69 72 85

ULYSSE COMMUNICATION
Bruno ARABIAN

barabian@ulysse-communication.com
+33 (0)6 87 88 46 26

Nicolas DANIELS

ndaniels@ulysse-communication.com
+33 (0)6 63 66 59 22